title: VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability.
abstract: BACKGROUND
  The machinery of early HIV-1 replication still remains to be elucidated. Recently the viral core was reported to persist in the infected cell cytoplasm as an assembled particle, giving rise to the reverse transcription complex responsible for the synthesis of proviral DNA and its transport to the nucleus. Numerous studies have demonstrated that reverse transcription of the HIV-1 genome into proviral DNA is tightly dependent upon proper assembly of the capsid (CA) protein into mature cores that display appropriate stability. The functional impact of structural properties of the core in early replicative steps has yet to be determined.
  
  
  RESULTS
  Here, we show that infectivity of HIV-1 mutants bearing S149A and S178A mutations in CA can be efficiently restored when pseudotyped with vesicular stomatitis virus envelope glycoprotein, that addresses the mutant cores through the endocytic pathway rather than by fusion at the plasma membrane. The mechanisms by which these mutations disrupt virus infectivity were investigated. S149A and S178A mutants were unable to complete reverse transcription and/or produce 2-LTR DNA. Morphological analysis of viral particles and in vitro uncoating assays of isolated cores demonstrated that infectivity defects resulted from disruption of the viral core assembly and stability for S149A and S178A mutants, respectively. Consistent with these results, both mutants failed to saturate TRIM-antiviral restriction activity.
  
  
  CONCLUSIONS
  Defects generated at the level of core assembly and stability by S149A and S178A mutations are sensitive to the way of delivery of viral nucleoprotein complexes into the target cell. Addressing CA mutants through the endocytic pathway may compensate for defects generated at the reverse transcription/nuclear import level subsequent to impairment of core assembly or stability.
authors.affiliation: Université Montpellier 1, Centre d'études d'agents Pathogènes et Biotechnologies pour Santé, France. sonia.brun@univ-montp1.fr
authors.forename: Sonia
authors.initials: S
authors.lastname: Brun
authors.forename: Maxime
authors.initials: M
authors.lastname: Solignat
authors.forename: Bernard
authors.initials: B
authors.lastname: Gay
authors.forename: Eric
authors.initials: E
authors.lastname: Bernard
authors.forename: Laurent
authors.initials: L
authors.lastname: Chaloin
authors.forename: David
authors.initials: D
authors.lastname: Fenard
authors.forename: Christian
authors.initials: C
authors.lastname: Devaux
authors.forename: Nathalie
authors.initials: N
authors.lastname: Chazal
authors.forename: Laurence
authors.initials: L
authors.lastname: Briant
mesh_terms: D002213:Capsid / Q000737:chemistry / Q000378:metabolism; D004279:DNA, Viral / Q000235:genetics / Q000502:physiology; D015497:HIV-1 / Q000235:genetics / Q000502:physiology*; D006801:Humans; D009154:Mutation; D014758:Viral Core Proteins / Q000378:metabolism; D019065:Virus Assembly / Q000235:genetics* / Q000502:physiology; D016662:Virus Integration
chemical_list: D004279:DNA, Viral; D014758:Viral Core Proteins